Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

References

• LevesqueMCBiologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?BioDrugs2012262657022385403
   PubMed Web of Science ®Google Scholar
• LinJZiringDDesaiSTNFalpha blockade in human diseases: an overview of efficacy and safetyClin Immunol20081261133017916445
   PubMed Web of Science ®Google Scholar
• Kálmán-SzekeresZOlajosMGanzlerKAnalytical aspects of biosimilarity issues of protein drugsJ Pharm Biomed Anal20126918519522633839
   PubMed Web of Science ®Google Scholar
• XieHChakrabortyAAhnJRapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologiesMAbs20102437939420458189
   PubMed Web of Science ®Google Scholar
• BeckAReichertJMApproval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industryMAbs20135562162323924791
   PubMed Web of Science ®Google Scholar
• ThorpeRWadhwaMBiosimilar monoclonal antibodies approved for use in the EUGaBI J201431910
   Google Scholar
• GottliebSBiosimilars: policy, clinical, and regulatory considerationsAm J Health Syst Pharm20086514 Suppl 6S2S8
   PubMed Web of Science ®Google Scholar
• AhmedIKasparBSharmaUBiosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United StatesClin Ther201234240041922244050
   PubMed Web of Science ®Google Scholar
• SchiestlMStanglerTTorellaCAcceptable changes in quality attributes of glycosylated biopharmaceuticalsNat Biotechnol201129431031221478841
   PubMed Web of Science ®Google Scholar
• TanQGuoQFangCCharacterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsMAbs20124676177423032066
   PubMed Web of Science ®Google Scholar
• MainiRNFeldmannMHow does infliximab work in rheumatoid arthritis?Arthritis Res20024Suppl 2S22S2712110154
   PubMedGoogle Scholar
• RahmanMUStrusbergIGeusensPDouble-blinded infliximab dose escalation in patients with rheumatoid arthritisAnn Rheum Dis20076691233123817392352
   PubMed Web of Science ®Google Scholar
• ZintzarasEDahabrehIJGiannouliSVoulgarelisMMoutsopoulosHMInfliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimensClin Ther200830111939195519108784
   PubMed Web of Science ®Google Scholar
• SörgelFLerchHLauberTPhysicochemical and biologic comparability of a biosimilar granulocyte colony-stimulating factor with its reference productBioDrugs201024634735720873878
   PubMed Web of Science ®Google Scholar
• JefferisRRecombinant antibody therapeutics: the impact of glycosylation on mechanisms of actionTrends Pharmacol Sci200930735636219552968
   PubMed Web of Science ®Google Scholar
• Lammerts van BuerenJJRispensTVerploegenSAnti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domainsNat Biotechnol201129757457621747378
   PubMed Web of Science ®Google Scholar
• PuthoorPRde ZoetenEFPediatric ulcerative colitis: the therapeutic road to infliximabBiol Ther2013311424392300
   PubMedGoogle Scholar
• ScallonBCaiASolowskiNBinding and functional comparisons of two types of tumor necrosis factor antagonistsJ Pharmacol Exp Ther2002301241842611961039
   PubMed Web of Science ®Google Scholar
• KnightDMTrinhHLeJConstruction and initial characterization of a mouse-human chimeric anti-TNF antibodyMol Immunol19933016144314538232330
   PubMed Web of Science ®Google Scholar
• VoulgariPVKaltsonoudisEPapagorasCDrososAAAdalimumab in the treatment of rheumatoid arthritisExpert Opin Biol Ther201212121679168622954150
   PubMed Web of Science ®Google Scholar
• FriesJFWilliamsCAMorfeldDSinghGSibleyJReduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategiesArthritis Rheum19963946166228630111
   PubMed Web of Science ®Google Scholar
• GenoveseMCvan den BoschFRobersonSALY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept studyArthritis Rheum201062492993920131262
   PubMed Web of Science ®Google Scholar
• DorvignitDPalaciosJLMerinoMExpression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case studyMAbs20124448849622647435
   PubMed Web of Science ®Google Scholar
• BirchJRRacherAJAntibody productionAdv Drug Deliv Rev2006585–667168516822577
   PubMed Web of Science ®Google Scholar
• QianJLiuTYangLStructural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestionAnal Biochem2007364181817362871
   PubMed Web of Science ®Google Scholar
• KawasakiNItohSHashiiNThe significance of glycosylation analysis in development of biopharmaceuticalsBiol Pharm Bull200932579680019420744
   PubMed Web of Science ®Google Scholar
• ChungCHMirakhurBChanECetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactoseN Engl J Med2008358111109111718337601
   PubMed Web of Science ®Google Scholar
• TakeuchiMInoueNStricklandTWRelationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cellsProc Natl Acad Sci U S A19898620781978222813359
   PubMed Web of Science ®Google Scholar
• HigashiHNaikiMMatuoSOkouchiKAntigen of “serum sickness” type of heterophile antibodies in human sera: indentification as gangliosides with N-glycolylneuraminic acidBiochem Biophys Res Commun1977792388395412499
   PubMed Web of Science ®Google Scholar
• KeatingGMPerryCMInfliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritisBioDrugs200216211114811985485
   PubMed Web of Science ®Google Scholar
• MainiRNBreedveldFCKaldenJRTherapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritisArthritis Rheum1998419155215639751087
   PubMed Web of Science ®Google Scholar
• ElliottMJMainiRNFeldmannMRandomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisLancet19943448930110511107934491
   PubMed Web of Science ®Google Scholar
• BeckABiosimilarBABiosimilar, biobetter and next generation therapeutic antibodiesMAbs20113210711021285536
   PubMed Web of Science ®Google Scholar